SCHEMBL21990270

SCHEMBL21990270

CC(C)(C)OC(=O)N1CC[C@H]2NC[C@H]2C1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.47
HPGD P15428 1/20 0.46
GPR119 Q8TDV5 6/20 0.44
RECQL P46063 1/20 0.43
EPHX1 P07099 1/20 0.43
MAPT P10636 2/20 0.43
KDM4E B2RXH2 1/20 0.43
THRB P10828 1/20 0.43
JAK2 O60674 1/20 0.43
JAK1 P23458 1/20 0.43
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
KMT2A Q03164 1/20 0.42
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PTPN2 P17706 1/20 0.40
PTPN1 P18031 1/20 0.40
PTPN6 P29350 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21801914 1.00 NR1H2 (0.47) NR1H2HPGDGPR119RECQLEPHX1
SCHEMBL30783208 1.00 NR1H2 (0.47) NR1H2HPGDGPR119RECQLEPHX1
Hydrochloric Acid SCHEMBL25343332 0.98 NR1H2 (0.46) NR1H2HPGDGPR119RECQLEPHX1
SCHEMBL1586009 0.88 GPR119 (0.47) NR1H2HPGDGPR119RECQLEPHX1
SCHEMBL927984 0.88 GPR119 (0.47) NR1H2HPGDGPR119RECQLEPHX1
SCHEMBL13760961 0.88 GPR119 (0.47) NR1H2HPGDGPR119RECQLEPHX1
SCHEMBL928825 0.88 GPR119 (0.47) NR1H2HPGDGPR119RECQLEPHX1
SCHEMBL25425866 0.87 GPR119 (0.46) NR1H2HPGDGPR119RECQLEPHX1
SCHEMBL22507954 0.86 NR1H2 (0.54) NR1H2HPGDGPR119RECQLEPHX1
SCHEMBL4871461 0.86 NR1H2 (0.54) NR1H2HPGDGPR119RECQLEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3512858-B1 FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2023-11-08 EP disclosed
US-10975100-B2 Fused bicyclic inhibitors of menin-MLL interaction JANSSEN PHARMACEUTICA NV (BE) 2021-04-13 US disclosed
US-20200172556-A1 FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2020-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200172556-A1 FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION MLLT1, BMI1, MEN1 NR1H2 1446/4885HPGD 2464/4885GPR119 1312/4885
US-10975100-B2 Fused bicyclic inhibitors of menin-MLL interaction MLLT1, BMI1, MEN1 NR1H2 1446/4885HPGD 2464/4885GPR119 1312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.